Tillkännagivande • Nov 07
Ambu A/S announces Annual dividend, payable on December 08, 2025 Ambu A/S announced Annual dividend of DKK 0.4100 per share payable on December 08, 2025, ex-date on December 04, 2025 and record date on December 05, 2025. Tillkännagivande • Oct 01
Ambu A/S, Annual General Meeting, Dec 02, 2026 Ambu A/S, Annual General Meeting, Dec 02, 2026. Tillkännagivande • Aug 22
Ambu A/S Revises Financial Guidance for the Year 2024/25 Ambu A/S revised financial guidance for the year 2024/25. For the period, the company revised organic revenue growth: 12% to 14% (previously 11% to 14%) and EBIT margin b.s.i.: 13% to 15%. Tillkännagivande • Jan 10
Ambu A/S Raises Financial Guidance for the Year 2024/25 Ambu A/S provided financial guidance for the year 2024/25. The outlook for organic revenue growth is set to 11-14% (previously 10-13%) and for EBIT margin before special items to 13-15% (previously 12-14%). Tillkännagivande • Nov 08
Ambu A/S Proposes Dividend The Board of Directors of Ambu A/S proposed a dividend of DKK 0.38 per share of nominally DKK 0.50 so that a dividend in the total amount of DKK 102 million be paid out of the net profit for the year, corresponding to 43% of the group's net profit, whereas the remaining part of the net profit be carried forward to next year. Reported Earnings • Nov 06
Full year 2024 earnings released: EPS: kr.0.88 (vs kr.0.65 in FY 2023) Full year 2024 results: EPS: kr.0.88 (up from kr.0.65 in FY 2023). Revenue: kr.5.39b (up 13% from FY 2023). Net income: kr.235.0m (up 40% from FY 2023). Profit margin: 4.4% (up from 3.5% in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 30
Ambu A/S to Report Q1, 2025 Results on Jan 30, 2025 Ambu A/S announced that they will report Q1, 2025 results on Jan 30, 2025 Reported Earnings • Sep 01
Third quarter 2024 earnings released: EPS: kr.0.50 (vs kr.0.19 in 3Q 2023) Third quarter 2024 results: EPS: kr.0.50 (up from kr.0.19 in 3Q 2023). Revenue: kr.1.38b (up 16% from 3Q 2023). Net income: kr.134.0m (up 163% from 3Q 2023). Profit margin: 9.7% (up from 4.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • May 15
Second quarter 2024 earnings released: EPS: kr.0.54 (vs kr.0.06 in 2Q 2023) Second quarter 2024 results: EPS: kr.0.54 (up from kr.0.06 in 2Q 2023). Revenue: kr.1.37b (up 15% from 2Q 2023). Net income: kr.144.0m (up kr.129.0m from 2Q 2023). Profit margin: 11% (up from 1.3% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 19% per year. Reported Earnings • Jan 31
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr.1.25b (up 11% from 1Q 2023). Net income: kr.92.0m (up 318% from 1Q 2023). Profit margin: 7.3% (up from 1.9% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Dec 14
Ambu A/S Elects Shacey Petrovic as Vice Chair of Board of Directors Ambu A/S at its Annual General Meeting held on December 13, 2023, elected Shacey Petrovic as Vice Chair of the Board of Directors. Tillkännagivande • Nov 18
Ambu A/S Announces Henrik Ehlers Wulff Not to Run for Re-Election for Board of Directors Ambu A/S at the Annual General Meeting to be held on 13 December 2023 Henrik Ehlers Wulff has decided not to run for re-election for Board of Directors. Tillkännagivande • Nov 09
Ambu A/S Provides Earnings Guidance for the Full-Year 2023/24 Ambu A/S provided earnings guidance for the full-year 2023/24 . For the year, the company expected total organic revenue growth 7-10% for the 2023/24 financial year, compared to 7.6% in 2022/23; EBIT before special items is expected to be 8-10%, compared to 6.3% in 2022/23. Reported Earnings • Sep 01
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr.1.20b (up 5.9% from 3Q 2022). Net income: kr.51.0m (up 82% from 3Q 2022). Profit margin: 4.3% (up from 2.5% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Tillkännagivande • Jul 12
Ambu A/S Raises Earnings Guidance for the Full-Year 2022/2023 Ambu A/S raised earnings guidance for the full-year 2022/2023. For the year, company expects EBIT margin before special items to 5% - 6% (previously 3% - 5%). Reported Earnings • May 03
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr.1.19b (up 6.0% from 2Q 2022). Net income: kr.15.0m (down 91% from 2Q 2022). Profit margin: 1.3% (down from 16% in 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 20% per year. Reported Earnings • Feb 08
First quarter 2023 earnings released: EPS: kr.0.09 (vs kr.0.08 in 1Q 2022) First quarter 2023 results: EPS: kr.0.09 (up from kr.0.08 in 1Q 2022). Revenue: kr.1.13b (up 9.8% from 1Q 2022). Net income: kr.22.0m (up 10.0% from 1Q 2022). Profit margin: 1.9% (in line with 1Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Tillkännagivande • Feb 07
Ambu A/S Provides Earnings Guidance for the Financial Year of 2022-2023 Ambu A/S provided earnings guidance for the financial year of 2022-2023. For the year, the company expected organic revenue growth is 5% to 8%. Board Change • Nov 22
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Susanne Larsson was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 16
Full year 2022 earnings released Full year 2022 results: Revenue: kr.4.44b (up 11% from FY 2021). Net income: kr.93.0m (down 62% from FY 2021). Profit margin: 2.1% (down from 6.2% in FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year. Buying Opportunity • Sep 17
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 1.1%. The fair value is estimated to be €11.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has declined by 21%. Revenue is forecast to grow by 26% in 2 years. Earnings is forecast to grow by 74% in the next 2 years. Reported Earnings • Aug 26
Third quarter 2022 earnings released: EPS: kr.0.11 (vs kr.0.24 in 3Q 2021) Third quarter 2022 results: EPS: kr.0.11 (down from kr.0.24 in 3Q 2021). Revenue: kr.1.13b (up 16% from 3Q 2021). Net income: kr.28.0m (down 55% from 3Q 2021). Profit margin: 2.5% (down from 6.4% in 3Q 2021). Over the next year, revenue is forecast to grow 16%, compared to a 7.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €9.30, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 37x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment deteriorated over the past week After last week's 25% share price decline to €9.36, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years. Reported Earnings • May 06
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: kr.1.12b (up 12% from 2Q 2021). Net income: kr.175.0m (up 84% from 2Q 2021). Profit margin: 16% (up from 9.5% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 25%, compared to a 11% growth forecast for the industry in Germany. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Director Henrik Wulff was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 09
First quarter 2022 earnings: Revenues and EPS in line with analyst expectations First quarter 2022 results: EPS: kr.0.08 (down from kr.0.37 in 1Q 2021). Revenue: kr.1.03b (up 1.8% from 1Q 2021). Net income: kr.20.0m (down 78% from 1Q 2021). Profit margin: 1.9% (down from 9.0% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 24%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Tillkännagivande • Feb 09
Ambu A/S Revises Revenue Guidance for the Fiscal 2022 Ambu A/S revised revenue guidance for the fiscal 2022. The outlook for organic growth is revised from 15% - 19% to 15% (15% or higher). Tillkännagivande • Feb 05
Ambu Announces FDA Clearance of Single-Use Gastroscope and Next-Generation Display Unit Ambu announced the 510(k) regulatory clearance of the Ambu® aScope™ Gastro and Ambu® aBox™ 2 in the United States. aScope Gastro is company's first sterile single-use gastroscope and includes new advanced imaging and design features in a combined solution with next-generation display and processor technology. With HD capabilities, the aBox 2 will set a new benchmark in terms of image quality and will be at the centre of company’s endoscopy ecosystem. With the launch of aScope Gastro, the company enters the gastroscopy segment, where 20 million procedures take place annually with reusable endoscope systems. The advanced technology, portability, and cost-effectiveness of company solution address the current limitations of reusable endoscopes, and it will be an attractive choice for customers looking to perform gastroscopies across a wide range of care settings (including endoscopy unit, OR, ICU, ER, ASC). Furthermore, the aScope Gastro will support healthcare systems in their efforts to reduce waiting lists and overcome staff shortages, which have been accentuated since the start of the COVID-19 pandemic. Finally, the sterile offering provides a solution to the growing cross-contamination risks, especially for vulnerable patients. Expanding Ambu’s presence in GI: Together with the launch of the aScope™ Duodeno 1.5, the aScope Gastro represents the next step in company expansion into the GI segment. They will be followed by the next generation single-use duodenoscope (aScope Duodeno 2.0), a colonoscope and a cholangioscope, giving company the most comprehensive single-use portfolio in GI. Upcoming Dividend • Dec 08
Upcoming dividend of kr.0.29 per share Eligible shareholders must have bought the stock before 15 December 2021. Payment date: 17 December 2021. Payout ratio is a comfortable 30% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (0.8%). Reported Earnings • Nov 12
Full year 2021 earnings released: EPS kr.0.98 (vs kr.0.98 in FY 2020) The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2021 results: Revenue: kr.4.01b (up 13% from FY 2020). Net income: kr.247.0m (up 2.5% from FY 2020). Profit margin: 6.2% (down from 6.8% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Board Change • Nov 09
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Vice-Chairman of the Board Christian Sagild was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
